TIDMPFZ
RNS Number : 1852Y
Pfizer Inc
01 March 2017
Media Relations Contact:
March 1, 2017 Joan Campion
212-733-2798
Investor Relations Contact:
Ryan Crowe
212-733-8160
It should be noted that the below was released in the U.S
February 28th, 2017
Pfizer Prices EUR4,000,000,000 Debt Offering
NEW YORK, N.Y., February 28 - Pfizer Inc. (NYSE: PFE) today
announced the pricing of a debt offering consisting of four
tranches of notes:
EUR1,250,000,000 aggregate principal amount of floating rate
notes due 2019
EUR1,000,000,000 aggregate principal amount of 0.000% notes due
2020
EUR1,000,000,000 aggregate principal amount of 0.250% notes due
2022
EUR750,000,000 aggregate principal amount of 1.000% notes due
2027
Interest on the floating rate notes will be three month EURIBOR
plus 0.20%, reset quarterly. Pfizer intends to use the net offering
proceeds for general corporate purposes, including to repay a
portion of its outstanding commercial paper.
Pfizer intends to apply to list the notes on the New York Stock
Exchange. The closing of the offering is expected to occur on March
6, 2017, subject to satisfaction of customary closing
conditions.
Barclays Bank PLC, BNP Paribas, Goldman, Sachs & Co. and
J.P. Morgan Securities plc are acting as joint book-running
managers for the offering.
The offering of these securities is being made only by means of
a prospectus. Copies may be obtained by calling Barclays Bank PLC
at +44 20 7773 9098, BNP Paribas at 1-800-854-5674, Goldman, Sachs
& Co. at 1-866-471-2526 or J.P. Morgan Securities plc at +44 20
7134 2468.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the notes, nor will there be
any sale of the notes in any jurisdiction in which such offer,
solicitation, or sale would be unlawful.
Working together for a healthier world(R)
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, we have worked to make a difference for
all who rely on us. We routinely post information that may be
important to investors on our website at www.pfizer.com. In
addition, to learn more, please visit us on www.pfizer.com and
follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube
and like us on Facebook at Facebook.com/Pfizer.
Forward-Looking Statements
This press release contains forward-looking statements made
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements involve substantial risks
and uncertainties. We have tried, wherever possible, to identify
such statements by using words such as "will," "may," "could,"
"likely," "ongoing," "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe," "target," "forecast," "goal,"
"objective," "aim" and other words and terms of similar meaning or
by using future dates in connection with any discussion of, among
other things, expectations regarding the completion of the notes
offering and the use of proceeds. A list and description of risks,
uncertainties and other matters can be found in our Annual Report
on Form 10-K for the year ended December 31, 2016, including in
the sections thereof captioned "Forward-Looking Information and
Factors That May Affect Future Results" and "Risk Factors," in our
Quarterly Reports on Form 10-Q, in our Current Reports on Form 8-K,
and in the prospectus supplement and accompanying prospectus, in
each case including in the section thereof captioned "Risk
Factors." You should understand that it is not possible to predict
or identify all such factors. Consequently, you should not consider
any such list to be a complete set of all potential risks or
uncertainties.
We cannot guarantee that any forward-looking statement will be
realized, although we believe we have been prudent in our plans and
assumptions. Achievement of anticipated results is subject to
substantial risks, uncertainties and inaccurate assumptions. Should
known or unknown risks or uncertainties materialize, or should
underlying assumptions prove inaccurate, actual results could vary
materially from past results and those anticipated, estimated or
projected. You should bear this in mind as you consider
forward-looking statements, and you are cautioned not to put undue
reliance on forward-looking statements. We undertake no obligation
to publicly update forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by law or by the rules and regulations of the Securities and
Exchange Commission (the "SEC"). You are advised, however, to
consult any further disclosures we make on related subjects in our
reports on Form 10-K, 10-Q and 8-K and our other filings with the
SEC.
# # # # #
This announcement has been issued through the Companies
Announcement Service of
The Irish Stock Exchange
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISESSASAFFWSELD
(END) Dow Jones Newswires
March 01, 2017 03:51 ET (08:51 GMT)
Pfizer (LSE:PFZ)
Historical Stock Chart
From Jan 2025 to Feb 2025
Pfizer (LSE:PFZ)
Historical Stock Chart
From Feb 2024 to Feb 2025
